Unplanned antiretroviral treatment interruptions, genetic barrier, and development of resistance

被引：4
|
作者：
Llibre, J. M. [1 ,2 ,3 ]
Young, B. [4 ,5 ]
机构：
[1] Univ Hosp Germans Trias & Pujol, Lluita SIDA Fdn, Badalona 08916, Spain
[2] Univ Hosp Germans Trias & Pujol, HIV Unit, Badalona 08916, Spain
[3] Univ Autonoma Barcelona, E-08193 Barcelona, Spain
[4] Int Assoc Providers AIDS Care, Washington, DC USA
[5] Univ Denver, Josef Korbel Sch Int Studies, Denver, CO USA
来源：
HIV MEDICINE | 2014年 / 15卷 / 04期
关键词：
NAIVE HIV-1-INFECTED PATIENTS; RITONAVIR-BOOSTED ATAZANAVIR; DISOPROXIL FUMARATE; INITIAL TREATMENT; PLUS RITONAVIR; EFFICACY; COBICISTAT; TENOFOVIR; REGIMENS; SAFETY;
D O I：
10.1111/hiv.12109
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：193 / 195
页数：3
相关论文
共 50 条
  • [41] Antiretroviral medication adherence and the development of class-specific antiretroviral resistance
    Gardner, Edward M.
    Burman, William J.
    Steiner, John F.
    Anderson, Peter L.
    Bangsberg, David R.
    AIDS, 2009, 23 (09) : 1035 - 1046
  • [42] Clinical significance of transient HIV type-1 viraemia and treatment interruptions during suppressive antiretroviral treatment
    Zhang, Shuangjie
    van Sighem, Ard
    Gras, Luuk
    Reiss, Peter
    Smit, Colette
    Kroon, Frank
    Jurriaans, Suzanne
    Prins, Jan
    Lange, Joep
    de Wolf, Frank
    ANTIVIRAL THERAPY, 2010, 15 (04) : 555 - 562
  • [43] MECHANISMS OF DISEASE Development of Antiretroviral Drug Resistance
    Wainberg, Mark A.
    Zaharatos, Gerasimos J.
    Brenner, Bluma G.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (07): : 637 - 646
  • [44] HIV integrase variability and genetic barrier in antiretroviral naive and experienced patients
    Piralla, Antonio
    Paolucci, Stefania
    Gulminetti, Roberto
    Comolli, Giuditta
    Baldanti, Fausto
    VIROLOGY JOURNAL, 2011, 8
  • [45] Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting
    Julg, Boris
    Dee, Lynda
    Ananworanich, Jintanat
    Barouch, Dan H.
    Bar, Katharine
    Caskey, Marina
    Colby, Donn J.
    Dawson, Liza
    Dong, Krista L.
    Dube, Karine
    Eron, Joseph
    Frater, John
    Gandhi, Rajesh T.
    Geleziunas, Romas
    Goulder, Philip
    Hanna, George J.
    Jefferys, Richard
    Johnston, Rowena
    Kuritzkes, Daniel
    Li, Jonathan Z.
    Likhitwonnawut, Udom
    van Lunzen, Jan
    Martinez-Picado, Javier
    Miller, Veronica
    Montaner, Luis J.
    Nixon, Douglas F.
    Palm, David
    Pantaleo, Giuseppe
    Peay, Holly
    Persaud, Deborah
    Salzwedel, Jessica
    Salzwedel, Karl
    Schacker, Timothy
    Sheikh, Virginia
    Sogaard, Ole S.
    Spudich, Serena
    Stephenson, Kathryn
    Sugarman, Jeremy
    Taylor, Jeff
    Tebas, Pablo
    Tiemessen, Caroline T.
    Tressler, Randall
    Weiss, Carol D.
    Zheng, Lu
    Robb, Merlin L.
    Michael, Nelson L.
    Mellors, John W.
    Deeks, Steven G.
    Walker, Bruce D.
    LANCET HIV, 2019, 6 (04): : E259 - E268
  • [46] Rapid In Vitro Evaluation of Antiretroviral Barrier to Resistance at Therapeutic Drug Levels
    Mulato, Andrew
    Hansen, Derek
    Thielen, Alex
    Porter, Danielle
    Stepan, George
    White, Kirsten
    Daeumer, Martin
    Cihlar, Tomas
    Yant, Stephen R.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2016, 32 (12) : 1237 - 1247
  • [47] A case report of clinical implications of a delayed antiretroviral therapy switch in a patient with multiple treatment interruptions
    Kakubu, Mireille A. Mpalang
    Frans, Kandali
    Gibutai, Nelson
    Katoto, Patrick D. M. C.
    SAGE OPEN MEDICAL CASE REPORTS, 2022, 10
  • [48] Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment
    Nuesch, R
    Ananworanich, J
    Sirivichayakul, S
    Ubolyam, S
    Siangphoe, U
    Hill, A
    Cooper, D
    Lange, J
    Phanuphak, P
    Ruxrungtham, K
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (05) : 728 - 734
  • [49] Multidrug resistance and response to antiretroviral treatment - Reply
    Fellay, J
    Back, D
    Schinkel, AH
    Eap, CB
    Telenti, A
    LANCET, 2002, 359 (9323): : 2114 - 2115
  • [50] Treatment interruptions to decrease risk of resistance emerging during therapy switching in HIV treatment
    Zurakowski, Ryan
    Wodarz, Dominik
    PROCEEDINGS OF THE 46TH IEEE CONFERENCE ON DECISION AND CONTROL, VOLS 1-14, 2007, : 5396 - +
12345